High-Sensitivity BD-pTau217 and BD-pTau181 Assays for Alzheimer’s Research

Quantify brain-derived phosphorylated tau in plasma or serum with femtogram-level sensitivity.

Eve Technologies is pleased to introduce new, high-sensitivity assays for brain-derived (BD) tau biomarkers on the Meso Scale Discovery® (MSD®) S-PLEX platform.

Each biomarker is available as an individual Research Use Only (RUO) assay with femtogram-level detection sensitivity.

The MSD® S-PLEX platform provides the analytical performance required to quantify these CNS-enriched tau species in plasma or serum, offering high sensitivity and excellent reproducibility.
Running BD-pTau217 and BD-pTau181 together yields complementary insight into Alzheimer’s-related neurodegeneration and disease progression.

Applications:

• Alzheimer’s disease and dementia research
• Longitudinal and progression studies
• Clinical-trial biomarker development (exploratory endpoints)
• Translational research bridging CSF and blood

Why BD-pTau Biomarkers Matter

Alzheimer’s research is rapidly shifting toward blood-based biomarkers that detect neurodegeneration earlier and more cost-effectively than cerebrospinal fluid (CSF) or PET imaging.
Among these, BD-pTau217 and BD-pTau181 have emerged as leading candidates for next-generation Alzheimer’s biomarkers.

Unlike conventional plasma tau assays, BD-pTau tests selectively measure CNS-specific tau isoforms, improving specificity for true neuronal injury while minimizing peripheral interference.

This makes them powerful tools for:

• Differentiating Alzheimer’s disease from other dementias
• Tracking progression and therapeutic response
• Translational studies linking CSF and blood biomarkers

Scientific Background

Tau protein stabilizes neuronal microtubules. In Alzheimer’s disease (AD) and related tauopathies, tau becomes abnormally phosphorylated and released into extracellular fluids such as CSF and blood.

Brain-derived (BD) tau assays selectively measure CNS-specific isoforms, improving specificity for neurodegeneration relative to total or peripheral tau.

For reference, standard plasma pTau217 (non-BD) has been shown across multiple studies to correlate strongly with amyloid-β and tau PET imaging and to predict cognitive decline in AD research cohorts.

When run in tandem, BD-pTau217 and BD-pTau181 provide a comprehensive research framework to differentiate AD from other dementias, track progression, and evaluate therapeutic interventions, while minimizing the peripheral confounds inherent to non-BD tau assays.

Regulatory Note: These assays are For Research Use Only (RUO) and not for diagnostic procedures.

Why Eve Technologies?

With over 20 years of multiplex immunoassay experience, Eve Technologies’ CLIA-regulated laboratory brings the technical precision, quality systems, and rigorous data standards necessary to generate publication-grade results.

Through our per-well pricing model, researchers can access cutting-edge biomarker assays for both cost-efficient pilot studies and large-scale translational research.

Key Advantages:

• MSD® S-PLEX platform implementation of BD-pTau217 and BD-pTau181
• Per-well pricing for cost efficiency
• Proven assay expertise — over two decades of multiplex immunoassay experience
• Publication-grade data — robust QC, transparent reporting, and fast turnaround
• Trusted by researchers worldwide, cited in over 3,600 peer-reviewed publications

Ordering Information

Each BD-Tau assay is available on a per-well basis for both small exploratory and large cohort studies.
All assays are Research Use Only (RUO) and not intended for diagnostic or patient-management purposes.